ACC Research (@ACCResearch1) header
ACC Research (@ACCResearch1) profile picture

ACC Research

@ACCResearch1

I am only an ACC patient and not an expert at all. The idea is simply to share the interesting articles I find and some good news to cheer us all up!

 Switzerland
facebook.com/ResearchAndAdenoidCysticCarcinoma/
Joined August 2017
  • Tweets415
  • Following6
  • Followers83
3Media
Photo by ACC Research (@ACCResearch1)Photo by ACC Research (@ACCResearch1)Photo by ACC Research (@ACCResearch1)
"Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022" #adenoidcysticcarcinoma bit.ly/3RovdLE

Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camreliz...

Initial data from trial of rivoceranib in combination with camrelizumab versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma...

globenewswire.com
2
"Detection & Characterization of Circulating Tumor Cells in #AdenoidCysticCarcinoma" bit.ly/3hwOZnY
1
1
"Increased retinoic acid signalling decreases lung metastasis in salivary #AdenoidCysticCarcinoma by inhibiting the noncanonical Notch1 pathway" bit.ly/3AKwWoJ
1
NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial @RWJBarnabas cinj.org/clinical-trials/fin…
Image from Rutgers Cancer Institute (@RutgersCancer)
2
6
"Single-cell immune mapping of #AdenoidCysticCarcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype." bit.ly/3NRuuAg
2
1
"Low‑dose radiotherapy combined with immunotherapy for suboral adenoid cystic carcinoma with bilateral lung metastasis: A case report and literature review" bit.ly/3nj3TRJ
1
"Rivoceranib Elicits Promising Responses in #AdenoidCysticCarcinoma " bit.ly/3zIl2vJ

Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma | OncLive

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or...

onclive.com
1
Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma. #hncsm #ASCO22 | @ASCO cancernetwork.com/view/activ…

Activity of Rivoceranib in Adenoid Cystic Carcinoma Showcased at ASCO 2022 | CancerNetwork

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.

cancernetwork.com
3
6
"Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of #AdenoidCysticCarcinoma : a preclinical study" go.nature.com/3b5UAlt
1
1
2
"Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) #AdenoidCysticCarcinoma (ACC) harboring Notch activating mutations (Notchmut)." bit.ly/3xkfTYV
"A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) #AdenoidCysticCarcinoma (ACC)." bit.ly/3GVfAHu
1
"Surgical Navigation, Augmented Reality, and 3D Printing for Hard Palate #AdenoidCysticCarcinoma En-Bloc Resection: Case Report and Literature Review" bit.ly/391tUlc
Surgical Navigation, Augmented Reality, and 3D Printing for Hard Palate Adenoid Cystic Carcinoma...

Surgical Navigation, Augmented Reality, and 3D Printing for Hard Palate Adenoid Cystic Carcinoma...

Adenoid Cystic Carcinoma is a rare and aggressive tumor representing less than 1% of head and neck cancers. This malignancy often arises from the minor salivary glands, being the palate its most...

pmc.ncbi.nlm.nih.gov
"Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic #AdenoidCysticCarcinoma : The SOLAR Trial" bit.ly/3GyCl3L
3
"Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic #AdenoidCysticCarcinoma in a Phase 2 Trial" bit.ly/3z6Jzdx

PharmiWeb.com – Thank you

After twenty-five years, PharmiWeb.com is closing. With gratitude to our community.

pharmiweb.com
1
3
NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial @RWJBarnabas cinj.org/clinical-trials/fin…
Image from Rutgers Cancer Institute (@RutgersCancer)
3
6
Trial - "Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma" bit.ly/3hwOZnY
1
NOW OPEN @RutgersCancer: “Detection & Characterization of Circulating Tumor Cells in Adenoid Cystic Carcinoma.” #ClinicalTrial #Carcinoma @RWJBarnabas #NationalCancerResearchMonth #NCRM22 cinj.org/clinical-trials/fin…
Image from Rutgers Cancer Institute (@RutgersCancer)
1
3
nitter.cf/CSCIColumbia/status/15…
Columbia Stem Cell Initiative (CSCI) (@CSCIColumbia) profile pictureColumbia Stem Cell Initiative (CSCI)@CSCIColumbia7 May 2022
Congrats to @CSCIColumbia @columbiacancer PhD student Sara Viragova (Dalerba lab) awarded the 1st prize for Early Career Scientists by @jedirarecancer for her work on inhibitors of retinoid signaling as anti-tumor agents in Adenoid Cystic Carcinoma #cancer
Image from Columbia Stem Cell Initiative (CSCI) (@CSCIColumbia)
1
"The anti-tumor effect of proteasome inhibitor MG132 for human #AdenoidCysticCarcinoma: correlate with the emerging role of Nrf2/Keap1 signaling pathway" bit.ly/3Pjswuz
1
Trial "Axitinib for Disease Progression" Eligible Conditions : #AdenoidCysticCarcinoma bit.ly/3MZ1arD
Load more